Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
pubmed:
31
1
2023
medline:
31
1
2023
entrez:
30
1
2023
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is molecularly heterogeneous, immune infiltrated, and selectively sensitive to immune checkpoint inhibition (ICI). Established histopathology paradigms like nuclear grade have baseline prognostic relevance for ccRCC, although whether existing or novel histologic features encode additional heterogeneous biological and clinical states in ccRCC is uncertain. Here, we developed spatially aware deep learning models of tumor- and immune-related features to learn representations of ccRCC tumors using diagnostic whole-slide images (WSI) in untreated and treated contexts (n = 1102 patients). We discovered patterns of nuclear grade heterogeneity in WSI not achievable through human pathologist analysis, and these graph-based "microheterogeneity" structures associated with PBRM1 loss of function, adverse clinical factors, and selective patient response to ICI. Joint computer vision analysis of tumor phenotypes with inferred tumor infiltrating lymphocyte density identified a further subpopulation of highly infiltrated, microheterogeneous tumors responsive to ICI. In paired multiplex immunofluorescence images of ccRCC, microheterogeneity associated with greater PD1 activation in CD8+ lymphocytes and increased tumor-immune interactions. Thus, our work reveals novel spatially interacting tumor-immune structures underlying ccRCC biology that can also inform selective response to ICI.
Identifiants
pubmed: 36712053
doi: 10.1101/2023.01.18.524545
pmc: PMC9882334
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
Nat Commun. 2021 Mar 12;12(1):1613
pubmed: 33712588
Cancer Res. 2022 Aug 3;82(15):2792-2806
pubmed: 35654752
Histopathology. 2017 Dec;71(6):918-925
pubmed: 28718911
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Nat Biotechnol. 2022 Apr;40(4):555-565
pubmed: 34795433
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Nat Ecol Evol. 2021 Jul;5(7):1033-1045
pubmed: 34002049
Biomed Res Int. 2014;2014:521380
pubmed: 24877109
JAMA Oncol. 2019 Nov 1;5(11):1631-1633
pubmed: 31486842
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
IEEE Trans Pattern Anal Mach Intell. 2021 Feb;43(2):567-578
pubmed: 31442971
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
Mol Cancer Res. 2022 Feb;20(2):202-206
pubmed: 34880124
PeerJ. 2014 Jun 19;2:e453
pubmed: 25024921
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Med Image Anal. 2019 Dec;58:101563
pubmed: 31561183
Clin Genitourin Cancer. 2022 Jun;20(3):e233-e243
pubmed: 35125301
Nat Med. 2020 Jun;26(6):909-918
pubmed: 32472114
Blood. 2021 Mar 11;137(10):1353-1364
pubmed: 32871584
Am J Surg Pathol. 2013 Oct;37(10):1490-504
pubmed: 24025520
Mol Cancer Res. 2021 Jun;19(6):979-990
pubmed: 33619226
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Cell. 2018 Apr 19;173(3):611-623.e17
pubmed: 29656891
Nat Cancer. 2020 Aug;1(8):800-810
pubmed: 35122049
J Immunother Cancer. 2019 May 28;7(1):139
pubmed: 31138299
JCO Clin Cancer Inform. 2019 Apr;3:1-7
pubmed: 30990737
IEEE Trans Image Process. 2000;9(4):735-44
pubmed: 18255446
Nat Commun. 2021 Feb 5;12(1):808
pubmed: 33547292